Efficacy and Safety of Tongren-Dahuoluo Bolus in Patients with Knee Osteoarthritis

NCT ID: NCT06674759

Last Updated: 2024-11-05

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-10
• Study Completion Date: 2025-12-30

Brief Summary

The clinical trial has a research cycle of 24 weeks. The first 12 weeks are multicenter, randomized, double-blind, controlled trials. A total of 72 patients with knee osteoarthritis with liver-kidney deficiency syndrome and/or cold-dampness arthralgia syndrome are planned to be enrolled and randomly assigned to the control group (Tongren-Dahuoluo Bolus) and the treatment group (Tongren-Dahuoluo Bolus Placebo) in a 1:1 ratio. The purpose is to compare the safety and efficacy of Tongren-Dahuoluo Bolus and placebo in treating knee osteoarthritis. A long-term blind extension study will be conducted in the next 12 weeks. All subjects will take Tongren-Dahuoluo Bolus orally to evaluate the long-term safety, tolerability, and efficacy of Tongren-Dahuoluo Pills in treating patients with knee osteoarthritis.

Conditions

Knee Osteoarthritis (Knee OA)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Treatment of Tongren Dahuoluo Pills

Group Type: EXPERIMENTAL

Tongren-Dahuoluo Bolus

Intervention Type: DRUG

0.72g,2 times a day, oral, for 24 weeks.

Treatment of Tongren-Dahuoluo Bolus Placebo

Group Type: PLACEBO_COMPARATOR

Tongren-Dahuoluo Bolus Placebo

Intervention Type: DRUG

0.72g,2 times a day, oral, for 12 weeks.

Interventions

Tongren-Dahuoluo Bolus

0.72g,2 times a day, oral, for 24 weeks.

Intervention Type: DRUG

Tongren-Dahuoluo Bolus Placebo

0.72g,2 times a day, oral, for 12 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female, aged 40 to 75 years old;

2. Meet the diagnostic criteria for primary knee osteoarthritis (KOA) (the diagnostic criteria refer to the 1995 American College of Rheumatology classification criteria for knee osteoarthritis);

3. Meet the diagnostic criteria for liver and kidney deficiency and (or) cold and dampness obstruction in the group standard of the Chinese Association of Traditional Chinese Medicine "Guidelines for Combination of Osteoarthritis Symptoms";

4. X-ray examination of the joints is graded as I to III (knee joint Kellgren/Lawrence e scoring standard);

5. Knee pain score ≥40mm in the past week (assessed by VAS standard);

Exclusion Criteria

1. Patients with other rheumatic diseases such as Sjögren's syndrome, gout, rheumatoid arthritis, or a history of human immunodeficiency virus (HIV);

2. Patients with severe lesions of important organs such as the heart, liver, and kidney, abnormal liver function (alanine or aspartate aminotransferase or glutamine transpeptidase>1.5 times the upper limit of normal value); or abnormal renal function (serum creatinine level> upper limit of normal value); white blood cell (white blood cell, WBC) or platelet (platelet, PLT) below the lower limit of normal value; or diabetic patients with poor blood sugar control in the recent period (glycosylated hemoglobin>8.0%);

3. Patients with suppurative, nonspecific, and other infectious knee arthritis;

4. Patients with traumatic, villonodular pigmentation and other lesions with knee synovium as the main lesions;

5. Patients with advanced joint deformity or disability; A randomized controlled study on Tongren Dahuoluowan in the treatment of knee osteoarthritis Version number: 2023009P8A01 Version date: December 23, 2022

6. Allergic constitution and allergic to the test drug;

7. Pregnant, pregnant, or lactating women;

8. Those who are taking antidepressants, anticonvulsants, opioids, sedatives and glucocorticoids;

9. Patients who have received intra-articular treatment with sodium hyaluronate within 4 weeks before screening; those who have taken drugs containing chondroitin sulfate/glucosamine/diacerein within 3 months before screening; those who have used biological agents within 3 months before screening;

10. Patients with organ failure symptoms;

11. Those who have participated in any other drug trials within 1 month before selection;

12. Those who the researcher believes are not eligible to join this clinical trial

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

OTHER

Sponsor Role: lead

Responsible Party

Quan Jiang

Director，Devision of Rheumatology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Quan Jiang

Role: CONTACT

doctorjq@126.com

86-010-88001060

Other Identifiers

2023-170-YW-01

Identifier Type: -

Identifier Source: org_study_id